RESEARCH TRIANGLE PARK, N.C.– IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced new global clinical and commercial partnerships along with the resolution of all pending legal disputes. The long-term agreement is designed to simplify how customers use the companies’ software, data, technology, and services together.
The partnerships establish broad integration across commercial and clinical operations. On the commercial side, master data and software third-party access agreements will enable IQVIA and Veeva data to be used across each other’s platforms. This includes IQVIA data in Veeva Network for master data management, Veeva Nitro for analytics, and Veeva AI, as well as Veeva data within IQVIA’s commercial products. IQVIA has also joined Veeva’s Technology, AI, and Services Partner Programs to support customer integrations.
On the clinical side, IQVIA has joined Veeva’s CRO Clinical Data Partner program, giving it the ability to leverage the Veeva Clinical Suite, including Veeva EDC, to streamline clinical trial execution. Customers will gain access to IQVIA’s data management and technology solutions combined with Veeva’s software to accelerate database builds, study locks, and data delivery.
“We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall,” said Peter Gassner, founder and CEO of Veeva. “I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers.”
“IQVIA and Veeva’s partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients,” added Ari Bousbib, chairman and CEO of IQVIA. “This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients.”
